Evidence map›Paper›PMID 35800233›Full record

ArticleContrast media & molecular imaging2022

The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.

Yaokai Ma, Guowei Liu, Jinzu Yang, Xin Li, Xiyi Yang, Shiming Fang, Baocheng Zhao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yaokai MaIntervention Department, Shanghai Xuhui Central Hospital, Shanghai, China.
Guowei LiuIntervention Department, Shanghai Xuhui Central Hospital, Shanghai, China.
Jinzu YangDepartment of Oncology, Shanghai Longhua Hospital, Shanghai, China.
Xin LiDepartment of Oncology, Shanghai Longhua Hospital, Shanghai, China.
Xiyi YangIntervention Department, Shanghai Xuhui Central Hospital, Shanghai, China.
Shiming FangIntervention Department, Shanghai Xuhui Central Hospital, Shanghai, China.
Baocheng ZhaoIntervention Department, Shanghai Xuhui Central Hospital, Shanghai, China.ORCID 0000-0003-2900-389X
Shanghai Xuhui Central Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the efficacy of combined therapy of Regorafenib with detoxicating and stasis softening Chinese herbal spleen tonics (DSS-splenic tonics) in mid-/late-stage hepatocellular carcinoma. Methods: Retrospective observational data of 120 patients were obtained, 60 of which received combined therapy of DSS-splenic tonics and regorafenib. Adverse event, overall survival (OS), and time-to-progress (TTP) were analyzed. Synergistic effect of DSS-spleen tonics was found and validated in human hepatocellular carcinoma HCCLM3 cell line and xenograft mouse models. Results: Combination of regorafenib and DSS-splenic tonics also slightly extended the TTP and OS compared with treatment of regorafenib alone, suggesting DSS-splenic tonics has synergistic effect with regorafenib. Both Regorafenib and DSS-spleen tonics exerted inhibitory effect on cell viability and invasion capability of HCCLM3 cells, and combining both could enhance the antitumor effect. At molecular level, we found that VEGF, HIF-1 Conclusion: DSS-spleen tonics could exert synergistic antitumor effect with regorafenib via targeting VEGF.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAnimalsChinaHumansMiceNiacinamidePhenylurea CompoundsPyridinesRetrospective StudiesSorafenibSpleenVascular Endothelial Growth Factor AAntineoplastic AgentsNiacinamidePhenylurea CompoundsPyridinesregorafenibSorafenibVascular Endothelial Growth Factor A

Identifiers

PMID35800233
PMCPMC9192279
OpenAlexW4285048785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.